Atherogenic dyslipidemia in diabetic nephropathy: lipoprotein (a), lipid ratios and atherogenic index

Suchitra MM, Sheshu Kumar M, Aparna R. Bitla, Madhusudhana Rao A, Alok S


Background: Atherogenic lipid profile is reported to become pronounced with onset of nephropathy. Lipid ratios also indicate atherogenic dyslipidemia. Lipoprotein (a) [(Lp(a)] considered as an independent risk factor for cardiovascular diseases (CVD), may play an important role in development and progression of nephropathy in type 2 diabetes mellitus (T2DM). The present study aimed to assess atherogenic dyslipidemia in T2DM and diabetic nephropathy patients.

Methods: Total cholesterol (TC), triglycerides(Tgl), high density lipoprotein (HDL), low density lipoprotein (LDL), very low density lipoprotein (VLDL), Lp(a), lipid ratios: TC/HDL, Tgl/HDL, LDL/HDL, non-HDL cholesterol and atherogenic index (AI) was assessed in T2DM (n=35), diabetic nephropathy (n=30) and healthy individuals (n=30). Means of biochemical parameters were compared by ANOVA (analysis of variance). Pearson correlation was performed to study the association between parameters. Receiver operating characteristics (ROC) curve analysis was done to assess the predictive ability of the variables.

Results: Atherogenic dyslipidemia with elevated Lp(a), TC, Tgl, VLDL, LDL, non-HDL cholesterol, lipid ratios, AI and low HDL levels were observed in both T2DM patients with and without nephropathy when compared to controls. Significantly high Tgl/HDL, TC/HDL and AI were observed in diabetic nephropathy when compared to T2DM.

Conclusion: T2DM and diabetic nephropathy are associated with dyslipidemia which was more pronounced in diabetic nephropathy. Elevated Lp(a) levels may be considered as an independent CVD risk marker in T2DM and diabetic nephropathy patients along with atherogenic lipid ratio indicators.


Atherogenic dyslipidemia, Lipid ratios, Atherogenic index, Cardiovascular disease, Diabetic nephropathy

Full Text:



Syed Shahid Habib. Cardiovascular disease in diabetes: An enigma of dyslipidemia, thrombosis and inflammation. Basic Res. J. Med. Clin. Sci. 2012; 1(3): 33-42.

Protasio Lemos da Luz, Desiderio Favarato, Jose Rocha Faria-Neto Junior, Pedro Lemos,, Antonio Carlos Palandri Chagas. High Ratio of Triglycerides to HDL-Cholesterol Predicts Extensive Coronary Disease. Clinics 2008; 63(4): 427–32.

Anne L. Peters. Clinical Relevance of Non-HDL Cholesterol in Patients With Diabetes. Clinical Diabetes 2008; 26(1): 3-7.

De Zeeuw D, Remuzzi G, Parving HH, F Keane W, Zhang Z, Shahinfar S et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL. Kidney Int 2004; 65: 2309-20.

Jaya Kumari S, Jayaram N, Vincent L, Venkatesh T. Serum lp(a) in diabetes with and without evidence of clinical nephropathy- A Preliminary study. Ind J of Clin Bioche 2002; 17(1):45-8.

Utermann G: The mysteries of lipoprotein(a). Science1989; 246:904-10.

Ariyo AA, Thach C, Tracy R. Lp(a) lipoprotein, vascular disease and mortality in the elderly. N Engl J Med 2003; 349:2108–15.

Fujino A, Watanabe T, Kunii H, Yamaguchi N, Yoshinara K, Watanabe Y et al. Lipoprotein(a) is a potential coronary risk factor. Jpn Circ J 2000; 64(1):51-6.

Gazzaruso C, Garzaniti A, Falcone C. Association of lipoprotein(a) levels and apolipoprotein(a) phenotypes with coronary artery disease in type 2 diabetic patients and in non-diabetic subjects. Diabet Med 2001;18:589-94.

Song KH, Ko SH, Kim HW, Ahn YB, Lee JM, Son HS. Prospective study of lipoprotein (a) as a risk factor for deteriorating renal function in type 2 Diabetic patients with overt proteinuria. Diabetes Care 2005; 28:1718-23.

Friedwald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without the use of the preparative ultracentrifuge. Clin Chem1992; 18:499-502.

Siems W, Carluccio F, Grune T, Jakstadt M, Quasts S, Hampl H et al. Elevated serum concentrations of cardio toxic lipid peroxidation products in chronic renal failure in relation to severity of anaemia. Clin Nephrol 2002; (Suppl1): 520-5.

Suryawanshi NP, Bhutney AK, Nagdeote AN, Jadhav AA, Manoorkar GS. Study of lipid peroxide and lipid profile in diabetes mellitus. Ind J of Clin Biochem 2006; 21(1):126-30.

Hirano T. Lipoprotein abnormalities in Diabetic nephropathy. Kidney Int1999; 56 (Suppl 71): 22-4.

Krolewski AS, Warram JH, Christlieb AR. Hypercholesterolemia: a determinant of renal function loss and deaths in IDDM patients with nephropathy. Kidney Int 1994; (Suppl 45):125–31.

Gunter Wolf, Eberhard Ritz. Diabetic Nephropathy in Type 2 Diabetes Prevention and Patient Management. J Am Soc Nephrol 2003; 14:1396–1405.

Bonnet F, Cooper ME. Potential influence of lipids in diabetic nephropathy: insights from experimental data and clinical studies. Diabetes and metabolism 2000; 26(4):254-64.

Jenkins AJ, Lyons TJ, Zheng D, Otvos JD, Lackland DT, McGee D, et al Lipoproteins in the DCCT/EDIC cohort study: associations with diabetic nephropathy. Kidney Int 2003; 64(3):817-28.

Navneet Agarwal, NS Sengar, PK Jain, Rashi Khare. Nephropathy in Newly Diagnosed Type 2 Diabetics with Special Stress on the Role of Hypertension. JAPI 2011; 59:145-7.

UI Nwagha, EJ Ikekpeazu, FE Ejezie, EE Neboh, IC Maduka. Atherogenic index of plasma as useful predictor of cardiovascular risk among postmenopausal women in Enugu, Nigeria. Afr Health Sci 2010; 10(3): 248–52.

Milionis HJ, Elisaf MS, Tselepis A, Bairaktari E, Karabina SA, Siamopoulos KC. Apolipoprotein (a) phenotypes and lipoprotein(a) concentrations in patients with renal failure. Am J Kidney Dis1999; 33:1100–6.

Boemi M, Sirolla C, Fumelli P, James RW. Renal disease as a determinant of increased lipoprotein (a) concentrations in diabetic patients. Diabetes Care1999; 22: 2033-6.

Heesen BJ, Wolffenbuttel BH, Leurs PB, Sels JP, Menheere PP, Jackle-Beckers SE, et al. Lp(a) levels in relation to diabetic complications in patients with non insulin dependent diabetes. Eur J Clin Invest 1993; 23(9): 580-4.

Humphrey LL, Ballard DJ, Frohnert PP, Chu CP, O'Fallon WM, Palumbo PJ. Chronic renal failure in non-insulin-dependent diabetes mellitus: A population based study in Rochester, Minnesota. Ann Intern Med1989; 111(10): 788-96.

Kishore J. Harjai. Potential new cardiovascular risk factors: Left Ventricular Hypertrophy, Homocysteine, Lipoprotein(a), Triglycerides, Oxidative stress, and Fibrinogen. Ann Intern Med1999; 131(5):376-86.

Seema S, Kiranjeet K, Gurdeep K, Harbir K, Jasbinder K, Shivani J. Lipoprotein(a) in type II diabetes mellitus: Relation to HDL:LDL ratio and glycemic control. Int J Diab Dev Ctries2009; 29(2): 80-4.

Ginter E, Simko V. Enigmatic lipoprotein (a) and cardiovascular diseases. Bratisl Lek Listy 2010; 111(10): 570-3.